Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT05011526

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

Covid19 Vaccine Clinical Trial

Official title:
A Phase III, Parallel Group, Prospective, Randomized, Double-blind, Active-controlled, Two-arm, Multi-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of MVC-COV1901 Compared to AZD1222 in Adults of 18 Years and Above

Clinical Trial Summary

The purpose of this study is to assess the immunogenicity and safety of MVC-COV1901 vaccine compared to AZD1222 in heathy adults.

Clinical Trial Description

The primary objective of the study is to measure the anti-SARS-CoV-2 neutralizing antibody titers in adult participants so as to demonstrate immunogenic superiority of MVC-COV1901 to the active control, AZD1222 vaccine, in terms of the GMT ratio of neutralizing antibodies at 14 days after the second dose of study intervention. This study also assesses the safety and tolerability of the study intervention and explores the immunogenicity in terms of anti-S IgG as well as the potential efficacy of MVC-COV1901 in preventing COVID-19. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05011526
Study type Interventional
Source Medigen Vaccine Biologics Corp.
Contact
Status Completed
Phase Phase 3
Start date October 8, 2021
Completion date May 21, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT05079633 - A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults Phase 4
Completed NCT04822025 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults Phase 2
Completed NCT04818892 - Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease
Completed NCT04951388 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents Phase 2
Not yet recruiting NCT04730895 - Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. Phase 1/Phase 2
Completed NCT05048849 - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study Phase 2
Completed NCT04765436 - PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64 Phase 1
Active, not recruiting NCT04760704 - Covid-19 Vaccine Response in Elderly Subjects
Completed NCT04695652 - A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult Phase 2
Withdrawn NCT05029245 - IntraDermal Versus Intramuscular Comirnaty® Efficacy Study Phase 3
Completed NCT05038618 - A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study Phase 2
Completed NCT05175742 - PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine. Phase 2
Recruiting NCT04834869 - COVID-19 Vaccines Safety Tracking (CoVaST)